BMS

Invitae is working with Bristol Myers Squibb, Janssen, Novartis, and Genentech to advance an NGS panel to gauge the efficacy of AML treatments in trials.

On the first day, Amgen detailed the rapid advancement of its KRAS inhibitor and Tempus unveiled an AI device to help oncologists deliver precision oncology. 

The firm also provided preliminary revenues of $950 million for Q4 and reinstated guidance of $3.79 billion to $3.88 billion for 2021.

The company aims to use the methylation technology from its multi-cancer screening assay to detect minimal residual disease in early-stage cancer patients.

Ikena will use the funding to advance its TEAD inhibitor into human trials and to pursue a preclinical program targeting KRAS signaling.

Opdivo plus chemotherapy extended survival for gastric cancer patients whose tumors expressed PD-L1 and in all comers in the Phase III CheckMate-649 trial.

Although the pandemic may have been at the forefront of readers' minds, they remained interested in the latest advances and controversies in precision oncology.

A data monitoring committee said that BMS's immunotherapy plus standard of care would not improve overall survival in MGMT-methylated brain cancer patients.

The consortium aims to harmonize the use of homologous recombination deficiency as a biomarker to guide certain treatment types in cancer patients.

The company decided this after the Keytruda-Yervoy combination did not improve overall survival or progression-free survival compared to Keytruda monotherapy.